- Home
- EDF vs TELO Comparison
EDF vs TELO Comparison
Compare EDF & TELO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- TELO
- Stock Information
- Founded
- EDF 2010
- TELO 2021
- Country
- EDF United States
- TELO United States
- Employees
- EDF N/A
- TELO N/A
- Industry
- EDF Investment Managers
- TELO
- Sector
- EDF Finance
- TELO
- Exchange
- EDF Nasdaq
- TELO NYSE
- Market Cap
- EDF 148.6M
- TELO 124.1M
- IPO Year
- EDF N/A
- TELO 2024
- Fundamental
- Price
- EDF $4.85
- TELO $3.73
- Analyst Decision
- EDF
- TELO
- Analyst Count
- EDF 0
- TELO 0
- Target Price
- EDF N/A
- TELO N/A
- AVG Volume (30 Days)
- EDF 160.6K
- TELO 61.7K
- Earning Date
- EDF 01-01-0001
- TELO 11-12-2024
- Dividend Yield
- EDF 13.14%
- TELO N/A
- EPS Growth
- EDF N/A
- TELO N/A
- EPS
- EDF N/A
- TELO N/A
- Revenue
- EDF N/A
- TELO N/A
- Revenue This Year
- EDF N/A
- TELO N/A
- Revenue Next Year
- EDF N/A
- TELO N/A
- P/E Ratio
- EDF N/A
- TELO N/A
- Revenue Growth
- EDF N/A
- TELO N/A
- 52 Week Low
- EDF $3.51
- TELO $3.11
- 52 Week High
- EDF $5.50
- TELO $20.72
- Technical
- Relative Strength Index (RSI)
- EDF 33.21
- TELO 35.99
- Support Level
- EDF $4.95
- TELO $4.11
- Resistance Level
- EDF $5.20
- TELO $4.54
- Average True Range (ATR)
- EDF 0.08
- TELO 0.33
- MACD
- EDF -0.02
- TELO -0.01
- Stochastic Oscillator
- EDF 5.78
- TELO 5.36
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund invests predominantly invests in fixed income securities and other instruments economically tied to emerging market countries.
About TELO TELOMIR PHARMACEUTICALS INC
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.